Diego Araiza MD

RT @ACVCPresident: ACVC School around the world continues 🫀 Another very successful edition held during C3 Acute Cardiovascular Congress held in Mexico City 🇲🇽 > 50 participants 🎉 International faculty 🌏 Unforgettable experience 🎯 Thank you all for making this collaboration possible See you next time 🚀 @drdargaray @PabloJ @JordiBaneras @carlosalviar @escardio #cvacute #education #simulation #cardiology #ACVC_ESC

RT @ACVCPresident: Are you a young doctor interested in critical care cardiology? Ready to showcase your research at THE transatlantic event in the area of #cvacute? Then this is an event made for you 💯 DEADLINE FOR SUBMISSION IN TWO DAYS 📣📣📣 #CCC26 Why apply? 🤔 This represents an extraordinary opportunity for trainees, and everyone else interested in critical cardiovascular care to submit abstracts and clinical cases. Why is this event so special? 💡 Selected cases will be featured on Cardio Nerds 🙋 Networking with 600+ attendees 🎓 Interaction with 100+ faculty from all around the 🌍 📖 Top abstracts will be published online And one special offer for #ACVC_ESC young members - FREE REGISTRATION for those who have their abstract accepted. 🏆 The selection will be made by chairs of ACVC Young community @JohannesGrand @StratinakiMaria Don't miss the opportunity and apply now 👩🏿‍💻 ℹ️More info here #Cardiology #NYU #CardioNerds #MedEd #CCU #Education @ATycinska @HannahSchaubro1 @drdargaray @jan_belohlavek @seanvandiepen @AlexMebazaa @CVandenbriele @RThachilMD @ShashankSinhaMD @drmilicaa @franciscojlk @rafavidalperez @EugenieDelaveau

RT @jorgericof: Comparto nuestro artículo más reciente . Es un trabajo multidisciplinario donde enfocamos el síndrome CRM desde una perspectiva en medicina de precisión. Es muy propositivo . Esperamos que sea de utilidad . Link @drdargaray @DrMauinforma @santy431 @CardiorenalCol @SLANH_

RT @carlosalviar: Starting tonight! 5th CCC online summit by @MedicalZoll free registration 👉 join us for amazing lectures by fantastic faculty! @drdargaray @AnnGageMD @ElliottMillerMD @ChrisBarnettMD @RThachilMD @emilyzernMD @valenjaramillo7 @schimmering @AndreaElliottUM

RT @escardio: A preliminary model to improve the prediction of cardiovascular risk in Latin America and the Caribbean was presented today at #ESCPrev26 We are proud to collaborate with @SIAC_cardio (SIAC) on this joint initiative to recalibrate SCORE2 using extensive data from Latin America and the Caribbean (LAC). The SCORE2 risk prediction system is based on data from European populations - SCORE2-LAC will deliver a new region-specific tool. The current burden of cardiovascular disease in Latin America and the Caribbean is high. SCORE2-LAC is an important project to help reduce critical geographic inequalities in CV health. Read the full details in our press release: #EAPC_ESC #cvprev #CardiovascularRisk #HeartHealth @EAPCPresident

RT @fundacion_fic: 📕Manual de Cuidados Agudos Cardiológicos: La guía definitiva para el manejo del paciente cardiológico crítico 💔 👩‍⚕️👨‍⚕️Coordinado por: @Ana_Viana_T @DrFerreraD @noriegafj y Rodrigo Fdez Jiménez @carlosalviar @drdargaray @PabloJ @JordiBaneras @CardioRed1

RT @Ana_Viana_T: Ya disponible el Manual de Cuidados Agudos Cardiológicos @carlosalviar @drdargaray @PabloJ @JordiBaneras

RT @CircAHA: #JustPublished: Global Rounds :Mexico: A Path Forward Through Integration

RT @hvanspall: Here are the pivotal #HF trials and their regional #enrolment Asia and African grossly under represented and all trials, but enrolment is improving in these regions. South America has made major gains. 3/4 @drdargaray

RT @hvanspall: In this 🌎 collaboration led by @GuiBaudry we assess regional #representativeness of pivotal HF #RCTs that have informed guidelines across world We acknowledge challenges in trial enrolment in #LMICs & offer strategies to address them 1/ @JavedButler1

RT @ACVCPresident: Holiday season is at the end and do you know what comes next? The first @escardio congress of the year #ACVC26 TOMORROW is the deadline for late breaking clinical trial submissions - if you have some raw research you still have time until noon CET And don't forget to register for an early fee discount - 7 days left. See you 🔜 in Lisbon. 🇵🇹

RT @ACVCPresident: Another beyond successful #ACVC_ESC School was held 14-15 November in @SimulacioVH ♨️ 8 stations ♨️ 70 participants ☀️ 21 countries 🌎 Experts from several continents Exchange of knowledge beyond borders - stay tuned and see you next year 🫀@escardio @sionis_a @JordiBaneras @carlosalviar @StratinakiMaria @drdargaray @Santi4614 @emireles_c @AndreaElliottUM #cvacute #Cardiology #education #simulation #ecmo #echofirst #leadership #Communication

RT @drpablocorral: 🚨 New breakthrough in prevention! 👉In the VESALIUS‑CV trial, Evolocumab added to high-intensity statin therapy reduced major adverse cardiovascular events (MACE) by 25% (HR 0.75; 95% CI 0.65-0.86) over ~4.6 years in patients who had no prior MI or stroke. 👉Absolute risk reductions: • ~1.8% for death from coronary disease, MI, or stroke. • ~2.8% when adding ischemia-driven revascularisation. 👉LDL-C fell ~55% to ~45 mg/dL—highlighting once again that “lower is better”, even before a first event. ☝️What this means for clinical practice: • This is the first PCSK9 inhibitor trial showing benefit in a “pre–first event” high-risk population, not just secondary prevention. • Identifying high-risk patients (e.g., established atherosclerosis, high-risk diabetes) before MI or stroke is crucial. • This supports aggressive LDL-C lowering to ~40 mg/dL in selected patients—even without prior event history. ☝️Take-home: For the right high-risk patient, adding evolocumab before the first major cardiovascular event can be a game-changer. Traditional prevention meets cutting-edge therapy. @society_eas

Is STEMI reperfusion a satisfied need? 🚩NO! - Most developing countries still face significant barriers for reperfusion So, let me take you through our new "Clinical Consensus Statement for STEMI reperfusion in LMICs, representing ACVC, EAPCI, EAPC, ESCWGT & SSL" A tweetorial

@ACVCPresident @carlosalviar @franciscojlk @rafavidalperez @STEMIindia @StentSaveLife @EAPCIPresident @EAPCPresident @alfocandiello @manuelchacon202 @gt_acs @ICBAonline @APCyCCV @AjitMullasari @smexcardiologia @SIAC_cardio @congresoC3 @JulioEffio @paomorejon @CNIC_CARDIO @MedscapeES @gonzaeperez 6 Finally, the clinical consensus provides advise on frequently faced, complex scenarios, including 🏳️Delayed access to pPCI 🏳️Delayed pPCI in cardiogenic shock 🏳️Delayed pPCI & high bleeding risk 🏳️No access to fibrin-specific Lytics. 🏳️Delayed access to scheduled pCI, etc

@ACVCPresident @carlosalviar @franciscojlk @rafavidalperez @STEMIindia @StentSaveLife @EAPCIPresident @EAPCPresident @alfocandiello @manuelchacon202 @gt_acs @ICBAonline @APCyCCV @AjitMullasari @smexcardiologia @SIAC_cardio @congresoC3 @JulioEffio @paomorejon @CNIC_CARDIO @MedscapeES @gonzaeperez The consensus emphasizes that these models, while pragmatic, are a starting point. Success requires continuous improvement, patient education campaigns, and adapting strategies to local realities. You can now read the full access paper in: #MedTwitter